|Post IPO Valuation|
|Venture Round, 10/2009 ||$35M|
|Venture Round, 4/2012 |
Threshold is a biotechnology company focused on the discovery and development of drugs targeting Tumor Hypoxia, the low oxygen condition found in microenvironments of most solid tumors.
This approach offers broad potential to treat most solid tumors. By selectively targeting tumor cells, they are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs.